AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:13 13/02/2026 GMT			5-day change	1st Jan Change
15,118.00 ^GBX	+1.42%		+7.19%	+9.63%

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT

ASTRAZENECA : Buy rating from UBS

Published on 01/16/2026 at 10:38 am GMT

MarketScreener with dpa-AFX Analyser

ASTRAZENECA PLC

+1.42%

In a research note published by Matthew Weston, UBS advises its customers to buy the stock. The target price has been revised upwards and is now set at GBX 16300, compared with GBX 14200 previously.

Latest news about AstraZeneca PLC

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
02-13	European Equities Mixed in Friday Trading; Spain's January CPI Declines	MT
02-13	AstraZeneca Announces Positive and clinically meaningful Results from the Phase III KALOS and Logos Trials for Breztri in Patients with Undundant Ast Astrazeneca's Breztri in Patients	CI
02-13	Shore Capital Downgrades AstraZeneca to Hold Rating	MT
02-13	Stocks edge lower ahead of US CPI data	AN
02-13	Stockholm Stock Exchange Declines on Friday After Intense Earnings Week	FW
02-13	ASTRAZENECA : Bernstein maintains a Buy rating	ZD
02-13	Bernstein, Barclays and Deutsche lower Relx	AN
02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-13	AstraZeneca rises on positive trial results for asthma therapy	AN
02-13	AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials	MT
02-13	NatWest results ahead of forecasts, ups dividend 51%	AN
02-13	Swedish Stocks in North America - Ericsson Up 0.9 Percent	FW
02-12	AbbVie sues US health agency over Botox price controls	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

03-02 - Daiwa Tokyo Investment Conference

More about the company